Show simple item record

dc.contributor.authorÖncül, Mustafa Oral
dc.contributor.authorDeniz, Günnur
dc.contributor.authorKüçüksezer, Umut Can
dc.contributor.authorÖktelik, Fatma Betül
dc.contributor.authorTahralı, İlhan
dc.contributor.authorAkdeniz, Nilgün
dc.contributor.authorÇetin, Esin
dc.contributor.authorÖğütmen, Yelda
dc.contributor.authorHeba, Hamida
dc.date.accessioned2021-12-10T10:40:54Z
dc.date.available2021-12-10T10:40:54Z
dc.identifier.citationKüçüksezer U. C. , Öktelik F. B. , Tahralı İ., Akdeniz N., Çetin E., Öğütmen Y., Heba H., Öncül M. O. , Deniz G., "Proliferative responses of patients infected with SARS‐Cov2 and the possible modulatory effects of C‐Vx as a candidate novel therapeutic against COVID‐19", ECI2021, Belgrade, Sırbistan, 1 - 04 Eylül 2021, ss.413
dc.identifier.othervv_1032021
dc.identifier.otherav_4e89ea01-de0e-4ab4-afc3-9c95fbb76c31
dc.identifier.urihttp://hdl.handle.net/20.500.12627/170393
dc.description.abstractCOVID 19 as a serious global health problem has led to investigation of immune responses against SARS‐Cov2, both for better understanding of the pathology and also for development of therapy options. C‐Vx was originally developed by Hamida Pharma‐USA in collaboration with Miracle Labs‐Turkey for cancer treatment. With COVID‐19 outbreak, alterations in C‐Vx formula were claimed to form a possible concomitant therapy option against COVID‐19. This study aimed to investigate the effects of C‐Vx on proliferative responses of T cell subsets and NK cells in COVID‐19 patients. Patients diagnosed with COVID‐19 (n=28; mild: 10, moderate: 8, severe: 10) and followed by Istanbul Faculty of Medicine, and healthy subjects (n=10) were enrolled. Ficoll‐purified PBMCs stained with CFSE were cultured with PHA, C‐Vx and their combination for 120 hours. Following cell culture, monoclonal antibodies against CD3, CD4, CD8, CD16 and CD56 were used for identification of cell subsets. C‐Vx induced proliferation of total PBMCs, CD3⁺, CD4⁺ and CD8⁺ T cells, the strongest in healthy subjects, the weakest in severe COVID‐19 patients. NK cells significantly responded to C‐Vx only in healthy controls. PHA‐induced proliferation of PBMCs, CD3⁺ and CD8⁺ T cells,and also NK cells were diminished with increased disease severity, which was regained to some extent with the presence of C‐Vx, in all cell populations but not in CD4⁺ T cells. The decreased proliferative responses with the severity of disease might indicate a disrupted immune function in severe COVID forms which could be re‐gained by C‐Vx.Keywords: Immune response tracing, Immunopharmacology, viral inf
dc.language.isoeng
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectGeneral Medicine
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectMedicine (miscellaneous)
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectİmmünoloji
dc.subjectMikrobiyoloji
dc.subjectTIP, GENEL & İÇECEK
dc.subjectİMMÜNOLOJİ
dc.subjectMİKROBİYOLOJİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMikrobiyoloji ve Klinik Mikrobiyoloji
dc.subjectImmunology and Microbiology (miscellaneous)
dc.subjectMicrobiology
dc.subjectFamily Practice
dc.subjectMicrobiology (medical)
dc.subjectFundamentals and Skills
dc.subjectGeneral Health Professions
dc.titleProliferative responses of patients infected with SARS‐Cov2 and the possible modulatory effects of C‐Vx as a candidate novel therapeutic against COVID‐19
dc.typeBildiri
dc.contributor.departmentİstanbul Üniversitesi , Aziz Sancar Deneysel Tıp Araştırma Enstitüsü , İmmünoloji Ana Bilim Dalı
dc.contributor.firstauthorID2749101


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record